Ubiquigent

We are in the process of transferring the Ubiquigent brand to a new owner, who may, in due course, provide future support to UPS research worldwide. We wish you all well with your future research and scientific endeavours.

To all our valued customers, collaborators, partners and suppliers, we regret to inform you that Ubiquigent Limited is no longer providing access to high-quality, validated reagents or services to support your Ubiquitin Proteasome System (UPS) related research.

Last call to submit to our DUBprofiler Open Access Initiative! Submit your DUB inhibitors for screening - gain insights into your non-proprietary compounds’ potency & selectivity to ensure your research & #drugdiscovery programmes have a strong foundation: [email protected]

Interested in learning more about the potency & selectivity of your compounds? Join our DUBprofiler Open Access Initiative & submit non-proprietary DUB modulators for screening against our gold standard #assay before 31 Jan. 💻 bit.ly/4f8GDOP 📩 [email protected]

📢Ubiquigent launches DUBprofiler Open Access Initiative Many #DUB inhibitors in the public domain have inadequately characterised selectivity. To counter this, we're inviting scientists to submit non-proprietary compounds for characterisation at no cost: bit.ly/4f8GDOP

We had a great time at #BIOEurope Autumn! 🍂 In case you missed us, there’s still time to schedule a meeting during the virtual partnering event on 12-13 November – contact us at [email protected] to find out more. #DrugDiscovery #DrugDevelopment #Pharma #Biotech #DUB

#BIOEurope has kicked off, bringing together industry leaders to discuss the future of biotech. Our team have a busy week ahead, meeting with partners, customers, and potential investors to share insights into our novel approach to DUB-focused #drugdiscovery.📩[email protected]

Next week, Hozefa Amijee and Rishi Shah will be at #BIOEurope,discussing how we are using our industry-leading platform to build a portfolio of novel DUB-targeting compounds to accelerate our partners’ programmes. Learn more: 💻ubiquigent.com 📩 [email protected]

We’re delighted to be partnering with @AlleoLabs to accelerate DUB-focused drug discovery! This collaboration will combine Alleo’s AI-based platform with our expertise in the DUB space to advance DUB-focused preclinical programmes. ➡ tinyurl.com/283d7o5o

🔔 Last chance to take advantage of our anniversary sale! Join us in celebrating 15 years of supporting researchers with a minimum 15% discount on all orders of our custom ubiquitin proteasome reagents until 31 Aug. 💻 rb.gy/35clhh 📩 [email protected]